By Nana O 
In a groundbreaking development poised to revolutionize the treatment of spinal cord injuries, researchers at The Texas Biomedical Device Center (TxBDC) at The University of Texas at Dallas (UT Dallas) have reported unprecedented rates of recovery in individuals with chronic, incomplete cervical spinal cord injuries. The novel therapeutic approach, detailed in a landmark study published in the prestigious journal Nature on May 21, combines targeted vagus nerve stimulation with progressive, individualized rehabilitation, leading to significant and meaningful improvements in upper-limb function.
A New Dawn for Spinal Cord Injury Recovery
For decades, the medical community has grappled with the devastating and often permanent consequences of spinal cord injuries. While rehabilitation therapies have offered some hope for regaining lost function, the extent of recovery has historically been limited, particularly for individuals with chronic injuries where nerve damage is established. This new study from UT Dallas, however, introduces a paradigm shift, demonstrating that even in cases where traditional therapy alone has proven ineffective, a synergistic approach can unlock remarkable restorative potential.
The study, which enrolled 19 participants with chronic, incomplete cervical spinal cord injuries, focused on enhancing arm and hand function. Participants underwent 12 weeks of intensive, individualized rehabilitation, engaging in simple video games designed to elicit specific upper-limb movements. Crucially, this therapy was coupled with closed-loop vagus nerve stimulation (CLV). This innovative technique involves the implantation of a miniature device in the neck that delivers precisely timed electrical pulses to the vagus nerve. These pulses are activated by the participants’ successful movements during rehabilitative exercises, creating a feedback loop that appears to amplify neural plasticity and promote the rewiring of damaged brain areas.
The Science Behind the Success: Amplifying Neural Reorganization
The efficacy of vagus nerve stimulation in neurological recovery is rooted in its ability to modulate brain activity. The vagus nerve, one of the longest cranial nerves, plays a significant role in regulating various bodily functions and is connected to key areas of the brain involved in motor control and learning. By stimulating the vagus nerve during rehabilitative efforts, researchers believe they are essentially "tagging" these movements as important, thereby encouraging the brain to reorganize and create new neural pathways to compensate for the injury.
This approach builds upon over a decade of dedicated research by UT Dallas investigators in neuroscience and bioengineering. Previous work by the TxBDC team had already shown promising results in stroke patients, where CLV, when added to standard physical therapy, significantly multiplied improvements in motor function. However, the current study presents a distinct and even more impactful scenario.
"In stroke, people who do only therapy may get better, and adding CLV multiplies that improvement," explained Dr. Michael Kilgard, the Margaret Fonde Jonsson Professor of Neuroscience at UT Dallas and the study’s corresponding author. "This study is different: Therapy alone for spinal cord injury didn’t help our participants at all." This stark contrast underscores the unique potential of CLV for spinal cord injury, suggesting it can initiate recovery where other methods fall short.
A Rigorous Clinical Trial Design
The clinical trial was meticulously designed as both a Phase 1 and Phase 2 study, incorporating a randomized placebo control in its initial phase. This robust design ensured the reliability of the findings. Nine of the 19 participants initially received sham stimulation, mimicking the sensation of active treatment without delivering therapeutic pulses, for the first 18 therapy sessions. They then transitioned to active CLV treatment for the subsequent 18 sessions. The remaining participants received active CLV from the outset. This controlled approach allowed researchers to isolate the effects of CLV and confirm its therapeutic benefits.
The participants in the study represented a diverse group, with ages ranging from 21 to 65 years. Their injuries varied in severity and duration, with the time elapsed since injury spanning from one to 45 years. A particularly noteworthy finding was the consistency of the treatment’s effectiveness across this varied population. Neither the age of the participant, the duration of their injury, nor the baseline severity of their impairment – as long as some hand movement was present – influenced the degree of response to the CLV therapy.
"This approach produces results regardless of these factors, which often cause significant differences in success rates of other types of treatment," stated Dr. Jane Wigginton, a study co-author, Chief Medical Officer at TxBDC, co-director of UT Dallas’s Clinical and Translational Research Center, and medical science research director at the Center for BrainHealth. Dr. Wigginton, who played a pivotal role in planning the clinical interactions and ensuring patient protections, described the results as "remarkable from a medical standpoint."
Tangible Improvements: Restoring Independence and Quality of Life
The impact of the CLV therapy was measured by tangible improvements in arm and hand strength, speed, range of motion, and overall function. These gains translate directly into enhanced daily living capabilities for individuals who have long been dependent on others for many tasks.
"These activities allow patients to regain strength, speed, range of motion and hand function. They simplify daily living," remarked Dr. Robert Rennaker, Professor of Neuroscience and the Texas Instruments Distinguished Chair in Bioengineering, who was instrumental in designing the miniature implanted CLV device. The ability to regain independence in basic tasks like feeding oneself, dressing, or using communication devices can profoundly improve an individual’s quality of life and self-esteem.
For many of the participants, this study offered a glimmer of hope in situations where conventional treatments had yielded little to no progress. "The people in this study have now gained the ability to do things that are meaningful for them and impactful in their lives," Dr. Wigginton emphasized, highlighting the profound personal significance of these functional recoveries.
A Stepping Stone to FDA Approval and Widespread Access
The success of this combined Phase 1/2 trial marks a critical milestone, paving the way for a pivotal Phase 3 clinical trial. This next stage is the final hurdle before seeking potential approval from the Food and Drug Administration (FDA) for the use of vagus nerve stimulation in treating upper-limb impairment resulting from spinal cord injury. The FDA has already approved vagus nerve stimulation for stroke patients with impaired upper-limb movement, based on TxBDC’s extensive 13-year research history with CLV across various conditions.
The newest generation of the implantable CLV device, developed by Dr. Rennaker, represents significant technological advancement. It is approximately 50 times smaller than earlier versions and importantly, does not interfere with common medical imaging procedures such as MRIs, CT scans, or ultrasounds, simplifying patient care and diagnostic follow-up.
The upcoming Phase 3 trial is designed to be even more extensive, involving approximately 70 participants across multiple specialized spinal cord injury centers in the United States. This larger, multi-institutional study will further validate the safety and efficacy of the CLV therapy on a broader scale and provide comprehensive data for regulatory review.
A Journey of Innovation and Collaboration
The path to this breakthrough has been long and arduous, involving the dedication of numerous researchers and collaborators. Dr. Seth Hays, Associate Professor of Bioengineering and a Fellow of the Eugene McDermott Distinguished Professor in the Erik Jonsson School of Engineering and Computer Science, has been involved in the CLV project since its inception.
"Prior to this study, no person with spinal cord injury had ever received CLV," Dr. Hays stated. "This is the first evidence that gains can be made. Now we will set about determining how we make this optimally effective." He cautioned, however, that the journey to widespread patient access is not guaranteed. "We still have a long road ahead. For many reasons — financial, regulatory or scientific — this could still die on the vine. But we have positioned ourselves to succeed."
The research team was keen to acknowledge the vital contributions of numerous individuals and institutions. The patients themselves demonstrated immense courage and commitment, participating in a novel and demanding treatment protocol. "These patients said, ‘Put that device in me’ — that’s a huge commitment. They deserve credit for paving the path for others," Dr. Rennaker noted.
Furthermore, the collaboration with partners at Baylor University Medical Center, Baylor Scott & White Research Institute, and Baylor Scott & White Institute for Rehabilitation was crucial to the study’s successful execution. "This has been the hardest working, most altruistic group of professionals, and that has been incredibly impactful," Dr. Wigginton added, underscoring the collective effort behind this scientific advancement.
Future Implications and the Road Ahead
The implications of this research extend far beyond the immediate participants. If approved, CLV therapy for spinal cord injuries could offer a life-changing treatment option for millions worldwide affected by this debilitating condition. The fact that the therapy appears to be effective regardless of injury duration or severity (within the scope of incomplete injuries) suggests a broad potential patient population.
The development of this therapy is also a testament to the power of interdisciplinary research, bridging neuroscience, bioengineering, and clinical medicine. The UT Dallas team, including researchers like Joseph Epperson, Emmanuel Adehunoluwa, Amy Porter, Holle Carey Gallaway, and David Pruitt, has consistently pushed the boundaries of what is possible in neural rehabilitation.
While the excitement surrounding these results is palpable, the scientific community remains grounded in the rigorous process of clinical validation. The upcoming Phase 3 trial will be critical in solidifying these findings and providing the data necessary for FDA approval. Should this therapy become widely available, it would represent a monumental leap forward in restoring function and independence for individuals living with spinal cord injuries, offering hope where previously there was little. The journey continues, but the progress made by the TxBDC team at UT Dallas offers a compelling vision of a future where spinal cord injuries are no longer a life sentence of permanent disability.
Funding for this research was provided by a grant (N66001-17-2-4011) from the Defense Advanced Research Projects Agency (DARPA), an agency of the Department of Defense, and the Wings for Life Accelerated Translational Program.